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Alfred Werner was awarded the Nobel Prize in Chemistry just over 100 years ago. We recall 
briefly the era in which he was working, his co-workers, and the equipment he used in his 
laboratories. His ideas were ground breaking: not only does a metal ion have a primary 
valency (“hauptvalenz”, now the oxidation state), but also a secondary valency, the 
coordination number (“nebenvalenz”). At that time some refused to accept this idea, but he 
realised that his new thinking would open up new areas of research. Indeed it did. We 
illustrate this for the emerging field of medicinal metal coordination chemistry, the design of 
metal-based therapeutic and diagnostic agents. The biological activity of metal complexes 
depends intimately not only on the metal and its oxidation state, but also on the type and 
number of coordinated ligands, and the coordination geometry. This provides a rich platform 
in pharmacological space for structural and electronic diversity. It is necessary to control both 
the thermodynamics (strengths of metal-ligand bonds) and kinetics of ligand substitution 
reactions to provide complexes with defined mechanisms of action. Outer-sphere interactions 
can also play a major role in target recognition. Our current interest is focussed especially on 
relatively inert metal complexes which were very familiar to Werner (Ru
II
, Os
II
, Rh
III
, Ir
III
, 
Pt
II
, Pt
IV
).  
 
Introduction 
Alfred Werner (1866 – 1919) was a child of Industrial Revolution. His scientific heritage 
helped to shape Chemistry as we know it today,
1, 2
 not only because he was awarded in 1913 
the first Nobel Prize in inorganic chemistry “in recognition of his work on the linkage of 
atoms in molecules by which he has thrown new light on earlier investigations and opened up 
new fields of research especially in inorganic chemistry", but also because – as pointed out in 
1966 by Leopold Horner “making full use of his ideas will be a task for generations.”  
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Figure 1. Alfred Werner and his Nobel Prize medal. Acknowledgement: Nachlass Alfred 
Werner, Zentralbibliothek der Universität Zürich. 
The First Industrial Revolution from about 1760 to around 1840, a period of transition to new 
manufacturing processes, evolved into the Second Industrial Revolution in the transition 
years between 1840 and 1870 with the large scale manufacture of machine tools and use of 
machinery in steam powered factories. It was in the 1820’s that Justus Freiherr von Liebig 
established the world’s first major School of Chemistry (at the University of Griessen, 
Germany) and initiated the chemical fertiliser industry.  
This time of dramatic evolution has led to the World as we know it today, a world in which 
Technology and Science not only accompany us, but inspire and drive the scientific progress 
and social evolution of Humankind. It is clear that the Industrial Revolution, as previously the 
Renaissance period, has deeply changed our perception of the world and of our own identity. 
This industrial golden age was accompanied and supported by great minds in a range of 
artistic, philosophical, and scientific domains. Such a relationship between an age of progress 
and the emergence of intellectual leaders can create a dynamic environment and a blast of 
creation that lasts for centuries.  
Beyond this scientific inheritance, Alfred Werner’s personality also reflects the societal 
challenges which accompanied the transitional and (R)evolutionary time. For instance, the 
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picture of Alfred Werner and co-workers in 1911 shown in Figure 2 strikingly highlights one 
of the current societal challenges in modern science, namely that of enhancing the role of 
women in science (three women out of 17 people can be seen on this picture). Very unusually 
at the beginning of the 20
th
 century, Werner’s research group was not only international, one 
of the reasons for the success of the best research groups in our current time, but was also 
marked by its high proportion of women students. Alfred Werner supervised 230 doctoral 
students, 22 women among them. Today at our own institution, The University of Warwick, 
for example, about one third of our PhD students are women. Interestingly, 1911 is also the 
year when Marie Curie won the Nobel Prize in Chemistry (after having shared the 1903 
Nobel Prize in Physics with her husband). The greatness of scientific research such as that of 
Werner relies not only on his/her brightness, intellectual vision and capability for innovating, 
but also on the ability of society to allow and enhance such greatness. There is no doubt that 
Alfred Werner is a typical example and a direct product from the golden age that was the end 
of the 19
th
 and beginning of the 20
th
 century, a golden age that he also helped to build, and 
which has had a major impact, producing many benefits we share today.  
 
Figure 2. Alfred Werner and his research group in 1911. Acknowledgement: Nachlass Alfred 
Werner, Zentralbibliothek der Universität Zürich 
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Figure 3. Some of the vessels (including platinum crucibles) used for synthesis in Werner’s 
laboratory. We thank Professor Roger Alberto for his assistance with this photograph. 
 
 
Figure 4. Some of the transition metal complexes synthesis by Werner and his co-workers. 
Their beautiful colours have long since made them attractive for study and are often useful 
for characterisation, including identification of coordination geometries, and distinction 
between isomers. Acknowledgement: Nachlass Alfred Werner, Zentralbibliothek der 
Universität Zürich. 
 
In this article, we focus on the impact of Werner’s ideas and discoveries in metal 
coordination chemistry on modern medicinal inorganic chemistry. This review does not aim 
to be comprehensive and is restricted largely to examples of precious metal coordination 
complexes (Pt, Ru, Os and Ir). We attempt to illustrate how vibrant the field of medicinal 
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inorganic chemistry is, and to relate recent fundamental advances to the pioneering work of 
Alfred Werner.  
Medicinal Inorganic Chemistry in a Nutshell 
Metal ions possess inherent properties such as preferred oxidation states and ligand 
geometries, but the overall reactivity of a metal complex also depends on the types and 
number of ligands and on the environment. Such variety and complexity makes inorganic 
chemistry an inexhaustible source of reactions that provide not only a huge reservoir (library) 
of molecules, but also presents a number of challenges to be overcome. Reduction and 
oxidation of the metal ion, or the bound ligands, ligand substitution, and (covalent and non-
covalent) reactions of the ligands at sites remote from the metal, are all potential reactions 
that may induce changes in the chemical and physical properties of metal complexes. Figure 
5 lists some features of metals and metal complexes that can be used in the design of such 
compounds for controlling their reactivity and tuning their properties. 
 
Figure 5. A metal coordination complex and some of the features which can be used in the 
design of metallodrugs (and diagnostic agents). 
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Alfred Werner’s contribution to the elucidation of the features shown in Figure 5 was 
essential. The modern IUPAC definition of valence is for instance is very similar to Werner’s 
definition of Hauptvalenz: 
 ‘‘The maximum number of univalent atoms (originally hydrogen or chlorine atoms) that may 
combine with an atom of the element under consideration, or with a fragment, or for which 
an atom of this element can be substituted’’.3  
The introduction by Werner of Nebenvalenz introduced the concept of coordination number 
and spatial arrangement of the ligands for a given metal centre. By extending isomer counting 
methods
4
 and by postulating that the Nebenvalenz is directed towards fixed positions in 
space, in the same way as the four valences of carbon are orientated in a tetrahedral 
geometry, Werner confirmed both the hexagonal planar structure of benzene and the 
octahedral geometry of the six ligands in six-coordinate cobalt(III) complexes. 
The pioneering work by Alfred Werner on the structure of metal complexes has provided a 
basis for inorganic chemists to understand that metallodrugs can provide unique mechanisms 
of drug action based on the choice of the metal, its oxidation state, the types and number of 
coordinated ligands and the coordination geometry. We have recently surveyed
5 
metal 
compounds, metal-chelating agents (metalloenzyme inhibitors) or other agents which 
interfere with metabolic pathways, including metal complexes currently undergoing clinical 
trials both for therapy and diagnosis. Moreover, inorganic medicinal chemistry can make use 
of both non-essential as well as essential elements for the design of drugs and diagnostic 
agents (Figure 6). Medicinal inorganic chemistry has been stimulated recently in particular by 
the success of platinum anticancer drugs (used as a component of nearly 50% of all cancer 
chemotherapy treatments), by the use of gadolinium(III) complexes as MRI contrast agents 
(about 20 million doses administered per year), and of the radionuclide 99m-technetium 
radiopharmaceuticals for γ-ray imaging (used in about 20 million radiodiagnostic procedures 
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each year). However, the involvement of metals in many other diseases and conditions are of 
current interest in relation to their causes, their treatment or detection, including 
neurodegeneration, microbial and parasitic (and other neglected tropical diseases) infections 
and inflammation.
6-9
 In the following sections, we will restrict the discussion to examples of 
precious metal anticancer drug candidates based on Pt, Ru, Os, and Ir. 
 
Figure 6. A medical periodic table: essential elements for man (symbols in white font); 
medical radioisotopes (green fill); elements currently used in therapy (blue fill) or diagnosis 
(orange fill). Reproduced with permission from reference
5
 (Copyright 2013, Royal Society of 
Chemistry Publishing). 
Platinum Complexes 
Alfred Werner devoted specific effort to investigations of the chemistry of platinum 
complexes and published 14 papers on this topic between 1896 and 1920.
10-23
 However, his 
interest in platinum(II) and platinum(IV) complexes spans more work than these 14 specific 
articles, and can be dated back to 1893 and publication of the first article on his co-ordination 
theory “Beitrag zur Konstitution anorganischer Verbindungen”.24 Alfred Werner’s research 
on the platinum metals was comprehensively reviewed by George B. Kauffman in 1997.
25
 A 
particularly essential piece of research from Werner in the context of this review on 
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bioinorganic chemistry is the disproof of the Blomstrand-Jøsrgensen chain theory for 
formulation of the isomers cis- and trans-[PtCl2(NH3)2]. Cis-[PtCl2(NH3)2] was first 
described by Michele Peyrone in 1844 (Peyrone's salt).
26
 Peyrone prepared the compound 
soon after moving to Liebig’s laboratory at the University of Giessen from Dumas’ 
laboratory in Paris. Peyrone was later to become an ardent defender of Liebig’s belief that 
plants can absorb ammonia and other nutrients from the soil that led to the concept of 
fertilisers and a revolution in agricultural practices.  
In 1893, Werner claimed that cisplatin and transplatin, at that time known as 
platosemidiammine and platosammine chlorides, respectively, adopt square-planar 
configurations rather than polymeric-type chain structures.
24
 The discovery of the 
antiproliferative property of cisplatin by Rosenberg, Van Camp, and Kigras in 1965
27
 led to 
the clinical success of this compound as an anticancer drug. Following this success, more 
than 4000 platinum compounds have been tested as potential anticancer drugs, leading to the 
worldwide approval for use in the clinic of two other platinum(II) complexes – carboplatin 
and oxaliplatin approved by the FDA in 1989 and 2002, respectively. Carboplatin and 
oxaliplatin are both blockbusters drugs
28
 that generated $673 M and $1,525 M of annual sales 
in 2004. A schematic representation of the effect and resistance mechanisms of platinum in 
cells is shown in Figure 7. 
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Figure 7. A schematic representation of cellular processes involving the anticancer drug 
cisplatin, including resistance mechanisms cells which can make the drug ineffective. 
A striking feature of the scheme in Figure 7 is the number of cancer cell resistance 
mechanisms towards platinum complexes that have been identified, including reduced uptake 
or increased efflux, complexation to sulfur ligands such as metallothionein or glutathione, or 
excision of Pt from DNA and repair of the damage. Side-effects may also accompany the 
treatment of cancer with platinum(II) complexes. Hence there is a need to design alternative 
metal-based anticancer drugs which can overcome the problems of resistance and side 
effects.  
In his paper published in 1893,
24
 Werner also argued that platinum(IV) complexes have an 
octahedral configuration. Octahedral low-spin 5d
6
 Pt
IV
 complexes are well known to be 
relatively inert towards ligand substitution, but can be activated chemically by reduction.
29-31
 
They are less susceptible to substitution reactions than square-planar platinum(II) complexes 
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and so as drugs are likely to undergo fewer reactions en route to the tumour. This may result 
in fewer undesired side-effects and reduced drug loss due to deactivation compared to 
platinum(II) complexes. Another advantage of Pt(IV) complexes is often their higher aqueous 
solubility.
32
 Hence, Pt(IV) complexes have potential advantages over Pt(II) as anticancer 
prodrugs,
33-36
 although reliance on activation by reduction may mean that their activity is less 
predictable since this will depend on the natural abundance and local concentrations of 
reductants such as thiols (e.g. glutathione) and ascorbate. 
The inertness of Pt(IV) has recently been exploited in our laboratory for the development 
photo-activated chemotherapeutic agents. In 2003, we developed a general method for the 
photoactivation of Pt
IV
-diazido complexes containing a variety of monodentate and chelated 
diamine ligands that allows the site-specific delivery of a wide range of Pt
II
-diamine drugs, 
and thus the possibility of a strong reduction of the unwanted side-effects often associated 
with platinum chemotherapy.
37
 This proof-of-concept work was followed by a number of 
reports highlighting the promise of this strategy. For instance, the complex trans, trans, 
trans-[Pt(N3)2(OH)2(NH3)(pyridine)] contains an octahedral Pt
IV
 centre with almost linear 
azido ligands, and is remarkably stable in the dark and in the presence of millimolar 
concentrations of glutathione. The complex readily undergoes photoinduced ligand 
substitution and photoreduction reactions. Its photoactivation in cells results in high toxicity 
(13–80 x more cytotoxic than cisplatin, and ca. 15 x more cytotoxic towards cisplatin-
resistant human ovarian cancer cells).
38
 It is notable that this is a trans diam(m)ine Pt(II) 
complex and that trans diam(m)ine Pt
II
 complexes were long thought to be inactive as 
anticancer agents since early studies demonstrated the inactivity of transplatin, trans-
[PtCl2(NH3)2]. Since then some examples of active trans diam(m)ine Pt(II) complexes have 
been reported.
39-43
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In 2009, the photocytotoxicity of a series of anticancer trans-dihydroxido 
[Pt(N3)2(OH)2(NH3)(X)] (X = alkyl or aryl amine) platinum(IV) diazido complexes was 
examined and the influence of cis-trans isomerism investigated. This study showed that trans 
isomers of complexes containing aliphatic or aromatic amines are more photocytotoxic than 
their cis isomers.
44
 The following year, the novel platinum(IV) diazido complex 
trans,trans,trans-[Pt(N3)2(OH)2(pyridine)2] was synthesised. It is stable in aqueous solution 
and also towards glutathione (GSH, the tripeptide γ-L-Glu-L-Cys_Gly, a reductant that 
protects cells from reactive oxygen species (ROS), and plays a major role in intracellular 
drug metabolism, especially in detoxification and deactivation of platinum anticancer 
drugs
45
). This bis-pyridine complex can be photoactivated with low doses, not only of UVA, 
but also of visible blue and green light to give potent antiproliferative activity, and exhibits 
strong cytotoxic effects in a number of cell lines at micromolar doses.
46
 Figure 8 illustrates 
the dramatic increases in activity towards ketatinocytes and ovarian cancer cells on changing 
the geometry of the amine ligands from cis to trans and the ammonia ligands to pyridines. 
Figure 8 also illustrates the greatly enhanced potency of the photoactivated Pt(IV) complexes 
compared to cisplatin used under the same conditions (short cell treatment time of about 1 
hour, and low irradiation dose- typical of procedures which might be used in the clinic). 
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Figure 8. Photoactivation of platinum(IV) complexes and comparison of their cytotoxic 
effects with cisplatin. The enhanced effect on photocytoxicity of introducing pyridine ligands 
is evident, 
The unusual photobiological properties of photoactivatable Pt
IV
 diazido complexes have been 
further investigated. They can kill human cancer cells by an apoptosis-independent 
mechanism.
47
 Rapid photo-reduction (UVA / blue) without amine loss, absence of cross-
resistance to cisplatin, potency in ovarian cancer cells and oesophageal cells both in vitro and 
in a xenograft cancer model,
47
 and strong DNA interactions (e.g. mono- and bi-functional 
DNA lesions, preference for G and C, large DNA unwinding angles, high percentage of 
interstrand cross links) have been demonstrated.
48
 The influence of the N-donor monodentate 
ligand L (pyridine vs. piperidine) on the chemical, DNA binding and cytotoxic properties of 
light activated trans,trans,trans-[Pt(N3)2(OH)2(NH3)(L)] was also investigated. The nature of 
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the heterocyclic nitrogen ligand, its basicity and lipophilicity, has a subtle inﬂuence on both 
the phototoxicity and photobiochemistry of this class of photo-chemotherapeutic agents.  
Recently, combined theoretical and computational molecular modeling and extensive 
experimental studies have been used to study possible DNA distortions induced by the major 
photoproduct of the platinum(IV) prodrug trans,trans,trans-[Pt(N3)2(OH)2(pyridine)2] as an 
interstrand cross-link of trans-{Pt(pyridine)2}
2+ 
to guanine N7 positions on each DNA 
strand.
49
 Such cross-links oﬀer possibilities for speciﬁc protein−DNA interactions and 
suggest possible mechanisms to explain the high potency of this photoactivated complex.  
Photoactivation of trans,trans,trans-[Pt(N3)2(OH)2(pyridine)2] can lead to the generation of 
azidyl radicals which can be trapped by the spin-trap DMPO and detected by electron 
paramagnetic resonance (EPR).
50
 The photocytotoxicity of trans,trans,trans-
[Pt(N3)2(OH)2(pyridine)2] can be modulated by low doses (500 μM) of the amino acid L-
tryptophan that can quench azidyl radicals. This opens up new perspectives for controlling 
the activity of photo-chemotherapeutic azido Pt
IV
 drugs. The photo-protection by L-Trp of 
photo-irradiated cells is shown in Figure 9. This study also suggests that the high potency of 
such photoactive platinum complexes may arise from their dual attack on cancer cells by 
radicals and Pt
II
 photoproducts. 
15 
 
 
Figure 9. Photo-protection of Pt
IV
 prodrug photo-irradiated living cells by addition of L-
tryptophan. Adapted from ref
50
 
Ruthenium, Osmium, and Iridium Complexes 
Despite the clinical success of platinum(II) metallodrugs and the clinical potential of 
platinum(IV) drug candidates, their limitations have led to intense research on metallodrugs 
containing other metals. Among them, ruthenium and osmium compounds are promising. 
Ruthenium complexes have raised considerable expectations for the treatment of cancer since 
the beginning of the 1990s.
51, 52
 Today, two ruthenium(III)-based anticancer drugs have 
successfully completed phase I clinical trials:
53, 54
 imidazolium-trans-dimethylsulfoxide-
imidazole-tetrachloridoruthenate (NAMI-A) and imidazolium-trans-bis(1H-indazole)-
tetrachloridoruthenate (KP1019). Organometallic arene Ru
II
 complexes such as [(η6-
biphenyl)Ru(en)Cl]
+
 (en = ethylenediamine)
55
 (11) and [(η6-p-cymene)Ru(PTA)Cl2]
56
 (p-
cymene = para-cymene and PTA = 1,3,5-triaza-7-phosphaadamantane) (12) have also been 
widely studied, and several others also show promise.
57-76
 Recently, different groups have 
investigated the chemical and biological activity of analogous half-sandwich arene osmium 
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complexes.
77-85
 Osmium, the heavier congener of ruthenium and a third row transition metal, 
commonly exhibits slower kinetics than ruthenium, and is often considered to be relatively 
inert. However, it is apparent that it is possible to tune the biochemical reactivity of arene 
osmium(II) complexes through understanding their aqueous solution chemistry.
86, 87
 
Different mechanisms of action have been investigated for explaining the anticancer activity 
of arene ruthenium complexes. Among these, interactions between complexes containing 
reactive Ru-Cl bonds and nuclear DNA can occur, through their hydrolysis and the formation 
of intermediary aqua complexes able to ruthenate DNA specifically at guanine residues.
88, 89
 
Interestingly, the first article written by Werner on ruthenium complexes was part of his 
series “Zur Theorie der Hydrolyse” published in 1907,16 and reported the behaviour of a 
bound hydroxido group. Thirteen years later, Werner published his second and last article 
about ruthenium complexes on the synthesis of 
hydroxonitrosylbis(ethylenediamine)ruthenium(III) compounds (general formula 
[Ru(OH)NO(en)2]X2, X being an halide and en = ethylenediamine).
23
 Interestingly, almost 80 
years later, ethylenediamine arene ruthenium complexes were shown to be a promising class 
of organometallic ruthenium anticancer drug candidates. A number of studies have 
demonstrated the in vitro and in vivo antitumoural activity of this type of complex.
90, 91
 Based 
on these promising results, we explored structurally related organometallics, particularly 
those containing phenylazopyridine ligands.
92
 These complexes are of particular interest due 
to their synthetic versatility: modification of the phenylazopyridine ligand, arene, and the 
halide all induce dramatic antitumoural modifications.
93
 Figure 10 shows the impact of such 
chemical modifications on the antiproliferative activity of osmium(II) azopyridine arene 
complexes.
94, 95
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Figure 10. Effect of the halido ligand and phenyl substituent on the activity of Os(II) 
phenylazopyridine arene complexes towards A2780 human ovarian cancer cells. 
Remarkably, the dimethylamino-phenylazopyridine osmium derivative is 10x more active 
than cisplatin in human ovarian cancer cells, and also shows high (nanomolar) potency in 
wide range of cancer cell lines, as demonstrated with both a US National Cancer Institute 
(NCI) 60 human tumour cell line anticancer drug screen (NCI60), and an in vivo therapeutic 
study, showing reduction in colorectal tumour volume and low general toxicity (little body 
weight loss) for this compound.
96
 
Promising also as anticancer agents are organometallic half-sandwich ‘piano-stool’ IrIII 
complexes.
97
 Somewhat surprisingly, low-spin 5d
6
 Ir
III
 complexes can be quite labile and 
readily exchange ligands. Ir
III
 is not readily stabilized by arenes but is stabilized by 
cyclopentadienyl ligands, and especially by pentamethylcyclopentadienyl. Some complexes 
of these cyclopentadienyl complexes can accept hydride from coenzyme nicotinamide 
adenine dinucleotide (NADH),
98
 and offer the possibility of killing cancer cells by redox 
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modulation reactions. The prospect of these complexes acting as catalytic drugs in cells is an 
intruiging one.
95
 
Finally we note that Werner’s coordination theory was able to account for the chirality of 
metal complexes (Figure 11) such as cis-[Co(en)2(NH3)2], which he resolved using (+)-
bromocamphorsulfonate as a counterion.
99
  
 
Figure 11. Werner realised that tris-chelation of an octahedral metal ion by three bidentate 
ligands creates a chiral complex. His models show the mirror images. Acknowledgement: 
Nachlass Alfred Werner, Zentralbibliothek der Universität Zürich. 
Half-sandwich organometallic complexes can also be chiral, for example when the legs of the 
piano stool are non-equivalent ligands. Chirality can have a major influence on biological 
activity since many biological target sites are themselves chiral (DNA, proteins). We have 
resolved the enantiomers of the chiral iodide p-cymene Os
II
 iminopyridine complexes shown 
in Figure 12 which contain chiral Os and chiral C centres.
100
 Interestingly in this case the 
enantiomers showed little difference in their average IC50 values (7.6 µM for ROs,RC and 9.6 
µM for SOs,SC) towards the 60 cancer cell lines in the NCI panel, consistent perhaps with a 
redox mechanism of action. 
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Figure 12. X-ray crystal structures of enantiomeric p-cymene Os
II
 iminopyridine complexes 
and their CD spectra. Adapted from ref
100
 
Conclusions 
Alfred Werner’s work on metal coordination complexes stemmed from his ability to visualise 
their structures in 3 dimensions. The practical demonstrations by him and his research group 
of the existence of both a primary valence (hauptvalenz, oxidation state,) and a secondary 
valence (nebenvalenz, coordination number) of a metal ion were remarkable achievements 
considering the very limited range of analytical techniques which they had available. They 
were especially skilled in synthesis, crystallisation and observation (of the colours of 
complexes). Similar to the Impressionists who, for the first time in the painting history, took 
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their canvases outside of their workshops and painted landscapes, thus opening-up new 
artistic movements at the end of the 19
th
 century, the work of Alfred Werner and other 
outstanding contemporary scientists was born from the foundations of the Industrial 
Revolution, and has since fed the entire science of the 20
th
 and early 21
st
 centuries. Werner 
had the foresight (in his Nobel speech) to realise that his introduction of these new concepts 
in coordination chemistry would provide long-lasting “opportunities for the investigation of 
new fields in inorganic chemistry, which are promising”. 
We have tried to illustrate here with a few examples that this is the case for the field of 
medicinal inorganic chemistry, and in particular the design of precious metal complexes as 
anticancer drugs. The examples are taken largely from work carried out in our own laboratory 
but several recent reviews are available which cover the wider field, including the 
biochemistry of gold,
101, 102
 platinum,
103-106
 and other inorganic and organometallic 
complexes,
62, 74-76, 107-114
 along with in-depth survey of their potential mechanisms of 
action.
101, 115-124 
The rich structural diversity of metal coordination complexes certainly presents an attractive 
platform for drug design. For example, an octahedral complex with six different ligands has 
15 enantiomeric pairs. The significance of dynamic processes which metal complexes can 
undergo might have not been fully appreciated by Werner. He worked largely with relatively 
inert complexes that retained their ligands during purification processes, including many 
octahedral d
3
 (e.g. Cr
III
) and low-spin d
6
 metal ions (e.g. Co
III
, Rh
III
, Ir
III
, Pt
IV
). However it 
has become apparent in the last 40 years or so that even these metal ions can be rendered 
labile by the appropriate choice of ligands, especially carbon ligands such as arenes and 
cyclopentadienyls in organometallic complexes. The challenge for medicinal coordination 
chemistry is then to control ligand substitutions processes so that the active form of the metal 
complex (the pharmacophore – the metal ion plus ligands) reaches and attacks the target site. 
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The existence of Werner’s coordination sphere therefore creates not only valuable 
pharmacological diversity, but also the problem of speciation as a result of ligand substitution 
(and perhaps redox reactions) in media where many other potential ligands are present. A 
major challenge now facing us is that of identifying species of metallodrugs in biological 
media, including cells and tissues. This is a very difficult task for which new methods are 
urgently needed. 
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